title: Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
abstract: The NF-κB pathway performs pivotal roles in diverse physiological processes such as immunity, inflammation, proliferation, and apoptosis. NF-κB is kept inactive in the cytoplasm through association with inhibitors (IκB), and translocates to the nucleus to activate its target genes after the IκBs are phosphorylated and degraded. Here, we demonstrate that loss of function of SHANK-associated RH domain interacting protein (SHARPIN) leads to activation of NF-κB signaling in skin, resulting in the development of an idiopathic hypereosinophilic syndrome (IHES) with eosinophilic dermatitis in C57BL/KaLawRij-Sharpin(cpdm)/RijSunJ mice, and clonal expansion of B-1 B cells and CD3(+)CD4(-)CD8(-) T cells. Transcription profiling in skin revealed constitutive activation of classical NF-κB pathways, predominantly by overexpressed members of IL1 family. Compound-null mutants for both the IL1 receptor accessory protein (Il1rap(tm1Roml)) and SHARPIN (Sharpin(cpdm)) resulted in mice having decreased skin disease severity. Inhibition of IκBA degradation by the proteasome inhibitor bortezomib alleviated the dermatitis in Sharpin(cpdm) mice. These results indicate that absence of SHARPIN causes IHES with eosinophilic dermatitis by NF-κB activation, and bortezomib may be an effective treatment for skin problems of IHES.
authors.affiliation: The Jackson Laboratory, Bar Harbor, Maine, USA.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Liang
authors.forename: Rosemarie E
authors.initials: RE
authors.lastname: Seymour
authors.forename: John P
authors.initials: JP
authors.lastname: Sundberg
mesh_terms: D000818:Animals; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D003872:Dermatitis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D020869:Gene Expression Profiling; D007150:Immunohistochemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D052002:NF-kappa B p50 Subunit / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D010641:Phenotype; D010766:Phosphorylation / Q000502:physiology; D011480:Protease Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D001897:Boronic Acids; D052002:NF-kappa B p50 Subunit; D009419:Nerve Tissue Proteins; D011480:Protease Inhibitors; D011719:Pyrazines; D051996:Transcription Factor RelA; C425287:sharpin; D000069286:Bortezomib
references.citation: N Engl J Med. 1994 Feb 24;330(8):535-8
references.pmid: 8302319
references.citation: Oncogene. 2006 Oct 30;25(51):6680-4
references.pmid: 17072321
references.citation: N Engl J Med. 2003 Dec 11;349(24):2334-9
references.pmid: 14668459
references.citation: Oncology. 2006;70(6):474-82
references.pmid: 17283449
references.citation: Semin Dermatol. 1995 Jun;14(2):122-8
references.pmid: 7640191
references.citation: Cancer Res. 1999 Jun 1;59(11):2615-22
references.pmid: 10363983
references.citation: Genes Dev. 2004 Sep 15;18(18):2195-224
references.pmid: 15371334
references.citation: Exp Dermatol. 2000 Oct;9(5):351-8
references.pmid: 11016856
references.citation: Cancer Treat Res. 2008;142:69-106
references.pmid: 18283783
references.citation: Am J Pathol. 1996 Mar;148(3):941-50
references.pmid: 8774148
references.citation: Clin Exp Immunol. 2001 Mar;123(3):505-10
references.pmid: 11298140
references.citation: Annu Rev Immunol. 2009;27:519-50
references.pmid: 19302047
references.citation: Clin Exp Immunol. 2007 Aug;149(2):217-25
references.pmid: 17590166
references.citation: J Cell Biol. 2000 May 29;149(5):999-1004
references.pmid: 10831603
references.citation: N Engl J Med. 1998 May 28;338(22):1592-600
references.pmid: 9603798
references.citation: Immunobiology. 2010 Apr;215(4):264-74
references.pmid: 19581018
references.citation: Ultrastruct Pathol. 1995 Mar-Apr;19(2):107-11
references.pmid: 7792947
references.citation: Genes Immun. 2007 Jul;8(5):416-21
references.pmid: 17538631
references.citation: N Engl J Med. 2008 Jun 26;358(26):2838-9; author reply 2839-40
references.pmid: 18579821
references.citation: Curr Opin Hematol. 2007 Jan;14(1):37-42
references.pmid: 17133098
references.citation: J Exp Med. 2007 Oct 29;204(11):2603-14
references.pmid: 17908936
references.citation: Exp Dermatol. 2010 Mar;19(3):252-8
references.pmid: 19650867
references.citation: PLoS One. 2007 Oct 03;2(10):e997
references.pmid: 17912374
references.citation: Blood. 2008 Sep 15;112(6):2500-7
references.pmid: 18539901
references.citation: N Engl J Med. 1999 Oct 7;341(15):1112-20
references.pmid: 10511609
references.citation: J Immunol. 1999 Apr 1;162(7):3890-6
references.pmid: 10201907
references.citation: CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37
references.pmid: 19278961
references.citation: J Gastroenterol Hepatol. 2003 Jun;18(6):712-8
references.pmid: 12753155
references.citation: Curr Opin Hematol. 2009 Jan;16(1):3-8
references.pmid: 19057198
references.citation: Cell Death Differ. 2006 May;13(5):861-72
references.pmid: 16470223
references.citation: Oncogene. 2006 Oct 30;25(51):6781-99
references.pmid: 17072328
references.citation: Oncogene. 2006 Oct 30;25(51):6831-43
references.pmid: 17072331
references.citation: J Clin Invest. 2001 Jan;107(1):3-6
references.pmid: 11134170
references.citation: Cell Mol Life Sci. 2005 Aug;62(15):1682-91
references.pmid: 15924263
references.citation: J Invest Dermatol. 1996 Feb;106(2):368-76
references.pmid: 8601744
references.citation: Allergy. 2004 Jul;59(7):673-89
references.pmid: 15180753
references.citation: Curr Opin Genet Dev. 2001 Jun;11(3):300-6
references.pmid: 11377967
references.citation: Best Pract Res Clin Rheumatol. 2008 Oct;22(5):863-82
references.pmid: 19028368
references.citation: Mol Cell Neurosci. 2001 Feb;17(2):385-97
references.pmid: 11178875
references.citation: Vitam Horm. 2006;74:229-54
references.pmid: 17027517
references.citation: Curr Opin Cell Biol. 1999 Apr;11(2):226-32
references.pmid: 10209157
references.citation: Orphanet J Rare Dis. 2007 Sep 11;2:37
references.pmid: 17848188
references.citation: Drugs. 2009;69(7):859-88
references.pmid: 19441872
references.citation: Hautarzt. 2007 Feb;58(2):122, 124-7
references.pmid: 17221241
references.citation: J Allergy Clin Immunol. 2007 Jun;119(6):1291-300; quiz 1301-2
references.pmid: 17399779
references.citation: Am J Pathol. 1993 Sep;143(3):972-82
references.pmid: 8362989
references.citation: Trends Immunol. 2006 Sep;27(9):428-33
references.pmid: 16861037
references.citation: J Biol Chem. 2004 Apr 2;279(14):13677-88
references.pmid: 14734551
references.citation: Toxicol Pathol. 2004 Mar-Apr;32(2):181-91
references.pmid: 15200156
references.citation: Eur J Immunol. 2001 Mar;31(3):734-42
references.pmid: 11241277
references.citation: FASEB J. 2009 Sep;23(9):2796-802
references.pmid: 19417085
references.citation: Vet Pathol. 2006 Jul;43(4):401-23
references.pmid: 16846982